Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
At FDA Public Meeting on LDT Regulation, Dx Firms, Labs Suggest Areas for Agency Attention
July 28, 2010
The two-day meeting held by the agency in Hyattsville, Md., drew comments from numerous LDT developers and in vitro diagnostic companies, each side presenting their views on the current bifurcated regulatory pathway and FDA's stated intent to regulate all LDTs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Ahead of FDA Meeting on LDTs, Test Developers Prep for Increased Oversight, but Greater Clarity
July 7, 2010 / Pharmacogenomics Reporter - Economic Model Finds MammaPrint More Cost-Effective than Oncotype; Highlights Need for Future Studies
May 9, 2012 / Pharmacogenomics Reporter - After Moving MammaPrint to FFPE Format, Agendia Sees Revenue Boost, Increasing Adoption
April 25, 2012 / Pharmacogenomics Reporter - Breast Cancer Test Makers Will Attempt to Sway UK's NICE in Wake of Initial Negative Opinion
February 8, 2012 / Pharmacogenomics Reporter - AMA Proposes New Coding Criteria for Multi-Analyte Algorithm-Based Tests
November 9, 2011 / Pharmacogenomics Reporter